Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linsitinib - Sling Therapeutics

X
Drug Profile

Linsitinib - Sling Therapeutics

Alternative Names: ASP-7487; Linsitinib - Astellas Pharma; OSI-906; OSI-906AA

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Astellas Pharma; Multiple Myeloma Research Foundation; Sling Therapeutics
  • Class Cyclobutanes; Imidazoles; Pyrazines; Quinolines; Small molecules
  • Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenocortical carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Graves ophthalmopathy
  • Preclinical Autoimmune disorders; Unspecified
  • Discontinued Adrenocortical carcinoma; Liver cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 11 Oct 2023 Sling Therapeutics initiates enrolment in a phase IIb/III extension trial for Graves ophthalmopathy in USA (PO) (NCT06112340)
  • 25 Sep 2023 Pharmacodynamics data from preclinical study in Graves ophthalmopathy released by Sling Therapeutics
  • 13 Sep 2023 Pharmacodynamics data from preclinical study in Graves ophthalmopathy released by Sling Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top